Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.